UA99634C2 - Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3 - Google Patents

Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3

Info

Publication number
UA99634C2
UA99634C2 UAA201006793A UAA201006793A UA99634C2 UA 99634 C2 UA99634 C2 UA 99634C2 UA A201006793 A UAA201006793 A UA A201006793A UA A201006793 A UAA201006793 A UA A201006793A UA 99634 C2 UA99634 C2 UA 99634C2
Authority
UA
Ukraine
Prior art keywords
c3alkyl
fluorinated
dopamine
formula
respond
Prior art date
Application number
UAA201006793A
Other languages
English (en)
Ukrainian (uk)
Inventor
Вільфрід Брайє
Шон Кольм ТЕРНЕР
Андреас ХАУПТ
Удо ЛАНГЕ
Ерве Женест
Карла ДРЕШЕР
Ліліане УНГЕР
Анна Люсія Йонген-Рело
Антон Бєспалов
Original Assignee
Ебботт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA99634(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ебботт Гмбх Унд Ко. Кг filed Critical Ебботт Гмбх Унд Ко. Кг
Publication of UA99634C2 publication Critical patent/UA99634C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение раскрывает соединения формулы (I) EMBED ISISServer , (I) в которой А представляет собой насыщенную или ненасыщенную углеводную цепь с длиной цепи от 4 до 6 атомов углерода, причем углеводная цепь не замещена или замещена 1, 2 или 3 метильными группами; R1 выбран из группы, состоящей из водорода, С1-С3алкила и фторированного С1-С3-алкила; R2 представляет собой водород, галоген, цианогруппу, С1-С3алкил, С1-С3алкоксигруппу, фторированный С1-С3алкил или фторированную С1-С3алкоксигруппу; R3 вибран из группы, що состоящей из разветвленного С4-С6-алкила и С3-С6циклоалкила, и R4 представляет собой С1-С6алкил, С3-С6циклоалкил, фторированный С1-С3алкил и фторированный С3-С6циклоалкил, физиологически приемлемые соли указанных соединений и их N-оксиды; фармацевтические композиции, на основе этих соединений, и способ лечения заболеваний, положительно реагирующих на антагонисты рецептора допамина D3 или агонисты допамина D3.
UAA201006793A 2007-11-02 2008-10-31 Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3 UA99634C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119927 2007-11-02

Publications (1)

Publication Number Publication Date
UA99634C2 true UA99634C2 (ru) 2012-09-10

Family

ID=40210491

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201006793A UA99634C2 (ru) 2007-11-02 2008-10-31 Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3

Country Status (29)

Country Link
US (1) US8492540B2 (ru)
EP (1) EP2217593B1 (ru)
JP (1) JP5559694B2 (ru)
KR (1) KR20100094491A (ru)
CN (1) CN101932574B (ru)
AR (1) AR069150A1 (ru)
AT (1) ATE556069T1 (ru)
AU (1) AU2008320814B2 (ru)
BR (1) BRPI0818726A2 (ru)
CA (1) CA2704533C (ru)
CL (1) CL2008003253A1 (ru)
CO (1) CO6280473A2 (ru)
CR (1) CR11410A (ru)
DO (1) DOP2010000126A (ru)
EC (1) ECSP10010227A (ru)
ES (1) ES2386691T3 (ru)
HK (1) HK1146628A1 (ru)
IL (1) IL205468A0 (ru)
MX (1) MX2010004830A (ru)
MY (1) MY154066A (ru)
NZ (1) NZ585051A (ru)
PA (1) PA8802101A1 (ru)
PE (1) PE20090950A1 (ru)
RU (1) RU2478633C2 (ru)
TW (1) TWI463984B (ru)
UA (1) UA99634C2 (ru)
UY (1) UY31448A1 (ru)
WO (1) WO2009056625A1 (ru)
ZA (1) ZA201003593B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014025993A1 (en) * 2012-08-08 2014-02-13 The Johns Hopkins University Inhibitors of d-amino acid oxidase
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR095264A1 (es) 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
KR102643833B1 (ko) 2022-06-30 2024-03-06 현대제철 주식회사 이강종 연연주시 강종 예측 정합성 증대 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
FR2727682A1 (fr) 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
FR2769913B1 (fr) * 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
TW200510395A (en) * 2003-06-05 2005-03-16 Abbott Gmbh & Co Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
DE102004027359A1 (de) * 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
DE602005018366D1 (de) * 2004-08-09 2010-01-28 Abbott Gmbh & Co Kg Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
CN101384263A (zh) * 2004-12-02 2009-03-11 艾博特股份有限两合公司 适合治疗对多巴胺d3受体调节产生反应的疾病的三唑化合物
DE102004061593A1 (de) * 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
CA2692268A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists

Also Published As

Publication number Publication date
JP2011502971A (ja) 2011-01-27
TW200927132A (en) 2009-07-01
MY154066A (en) 2015-04-30
US20100311755A1 (en) 2010-12-09
AR069150A1 (es) 2009-12-30
KR20100094491A (ko) 2010-08-26
CN101932574A (zh) 2010-12-29
PE20090950A1 (es) 2009-08-08
UY31448A1 (es) 2009-05-29
BRPI0818726A2 (pt) 2015-04-22
DOP2010000126A (es) 2010-06-15
ES2386691T3 (es) 2012-08-27
EP2217593A1 (en) 2010-08-18
JP5559694B2 (ja) 2014-07-23
AU2008320814B2 (en) 2013-07-11
PA8802101A1 (es) 2009-08-26
ATE556069T1 (de) 2012-05-15
RU2478633C2 (ru) 2013-04-10
ZA201003593B (en) 2011-02-23
CA2704533A1 (en) 2009-05-07
ECSP10010227A (es) 2010-08-31
MX2010004830A (es) 2010-10-20
HK1146628A1 (en) 2011-06-24
RU2010122337A (ru) 2011-12-10
CN101932574B (zh) 2014-07-23
IL205468A0 (en) 2010-12-30
NZ585051A (en) 2012-03-30
CL2008003253A1 (es) 2009-11-13
AU2008320814A1 (en) 2009-05-07
WO2009056625A1 (en) 2009-05-07
US8492540B2 (en) 2013-07-23
CO6280473A2 (es) 2011-05-20
TWI463984B (zh) 2014-12-11
CR11410A (es) 2010-09-13
CA2704533C (en) 2016-09-06
EP2217593B1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
PH12013500848A1 (en) Trpv1 antagonists and uses thereof
UA101601C2 (ru) Ингибиторы амидогидролазы жирных кислот
WO2008076243A3 (en) Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
PL1921919T3 (pl) Ulepszona lipolityczna formulacja o podtrzymywanym uwalnianiu do traktowania lokalnej tkanki tłuszczowej
WO2006119507A3 (en) Non-nucleotide composition and method for inhibiting platelet aggregation
UA99361C2 (ru) ТРИАЗИНЫ КАК ИНГИБИТОРЫ PI3-КИНАЗЫ I mtor
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
UA99634C2 (ru) Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
WO2009061374A3 (en) Deuterated fingolimod
DE602004027409D1 (de) Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
TW200633710A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
MX2010004300A (es) Ligandos de (1,4-diaza-biciclo [3,2,2]non-6-en-4-il)-heterociclil- metanona para receptores nicotinicos de acetilcolina, utiles para el tratamiento de enfermedad.
MX2009008777A (es) Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
EA201070603A1 (ru) Лекарственное средство, активное в отношении невропатической боли
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
WO2008059130A9 (fr) Thionucléosides et applications pharmaceutiques
TW200510395A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
MX2009012933A (es) Derivados de ariloxazol ariloxadiazol y bencimidazol como moduladores de la actividad del receptor de somatostatinas.
UA99628C2 (ru) Бензолсульфонамидные соединения, пригодные для лечения расстройств, восприимчивых к модуляции дофаминового рецептора d3